Molecular Formula | C16H11F4N3O2S |
Molar Mass | 385.34 |
Density | 1.51±0.1 g/cm3(Predicted) |
Melting Point | 167-169°C |
Boling Point | 519.8±60.0 °C(Predicted) |
Solubility | DMSO |
Appearance | Solid |
Color | Off-White to Pale Beige |
pKa | 9.67±0.10(Predicted) |
Storage Condition | 2-8°C |
Use | Mavacoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) ,with Anti-Tumour activity. |
Target | COX-2 |
In vivo study | Osteoarthritic dogs enrolled in the studies are randomized to receive treatment with Mavacoxib and daily placebo for carprofen or placebo for Mavacoxib and daily carprofen at a nominal dose of 4 mg/kg BW. Mavacoxib is administered in both studies with a 2-week interval between the first and second doses but with monthly dosing thereafter. The nominal Mavacoxib doses in Studies 1 and 2 are 4 and 2 mg/kg BW, respectively. Seven Mavacoxib doses are administered in Study 1, but only five doses in Study 2. In Study 1, Mavacoxib is administered without regard to the timing of meals, but in Study 2, all of the Mavacoxib doses are administered with food. |
Reference Show more | 1. Hurst EA, et al. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels. Vet Comp Oncol. 2019 Jun;17(2):194-207.2. Cox SR, et al. Population pharmacokinetics of mavacoxib in osteoarthritic dogs. J Vet Pharmacol Ther. 2011 Feb;34(1):1-11. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.595 ml | 12.976 ml | 25.951 ml |
5 mM | 0.519 ml | 2.595 ml | 5.19 ml |
10 mM | 0.26 ml | 1.298 ml | 2.595 ml |
5 mM | 0.052 ml | 0.26 ml | 0.519 ml |